PMID- 34054947 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210601 IS - 1687-8337 (Print) IS - 1687-8345 (Electronic) IS - 1687-8337 (Linking) VI - 2021 DP - 2021 TI - MiR-122 Participates in Oxidative Stress and Apoptosis in STZ-Induced Pancreatic beta Cells by Regulating PI3K/AKT Signaling Pathway. PG - 5525112 LID - 10.1155/2021/5525112 [doi] LID - 5525112 AB - At present, there are few reports concerning the relationship between miR-122 and diabetes. In addition, the effect of miR-122 on streptozotocin- (STZ-) induced oxidative damage in INS-1 cells remains unclear. The present study aimed to investigate the role and modulatory mechanisms involving miR-122 in diabetes. STZ was used to induce INS-1 cell damage. Reverse transcription-quantitative PCR was used to investigate the expression of miR-122. A TUNEL cell apoptosis detection kit was used to detect apoptosis. Intracellular ROS levels were determined using dichlorofluorescein-diacetate. The activities of insulin secretion, superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-px) were measured using ELISA kits. Western blotting was used to measure the expression levels of Bax, Bcl-2, PI3K, p-PI3K, caspase-3 and caspase-9, cleaved-caspase-3 and cleaved-caspase-9, AKT, and p-AKT. Then, LY294002 (LY, PI3K inhibitor) was used to treat INS-1 cells, and oxidative stress and apoptosis were measured. The results showed that STZ-induced inhibitory effects on insulin secretion were mitigated by miR-122 inhibitor, and the activities of SOD, CAT, and GSH-px were also increased. Furthermore, miR-122 inhibitor inhibited apoptosis and oxidative stress in STZ-induced INS-1 cells. Finally, the addition of LY increased insulin levels; reduced the activities of SOD, CAT, and GSH-px; and promoted apoptosis in STZ-induced INS-1 cells. In conclusion, interference with miR-122 can inhibit oxidative stress and apoptosis in STZ-induced INS-1 cells, involving a mechanism of action related to the PI3K/AKT pathway. CI - Copyright (c) 2021 Jing Wang et al. FAU - Wang, Jing AU - Wang J AUID- ORCID: 0000-0001-7531-5056 AD - Department of Endocrinology, Rheumatism and Immunology, Shengzhou People's Hospital, The First Affiliated Hospital of Zhejiang University Shengzhou Branch, Zhejiang, Shengzhou 312400, China. FAU - Dong, Zhichun AU - Dong Z AUID- ORCID: 0000-0001-7541-8741 AD - Department of Endocrinology, Rheumatism and Immunology, Shengzhou People's Hospital, The First Affiliated Hospital of Zhejiang University Shengzhou Branch, Zhejiang, Shengzhou 312400, China. FAU - Lou, Liyin AU - Lou L AUID- ORCID: 0000-0001-5259-3117 AD - Department of Endocrinology, Rheumatism and Immunology, Shengzhou People's Hospital, The First Affiliated Hospital of Zhejiang University Shengzhou Branch, Zhejiang, Shengzhou 312400, China. FAU - Yang, Lijuan AU - Yang L AUID- ORCID: 0000-0002-6000-6530 AD - Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, Shengzhou 312400, China. FAU - Qiu, Jingying AU - Qiu J AUID- ORCID: 0000-0002-6528-1355 AD - Department of Endocrinology, Rheumatism and Immunology, Shengzhou People's Hospital, The First Affiliated Hospital of Zhejiang University Shengzhou Branch, Zhejiang, Shengzhou 312400, China. LA - eng PT - Journal Article DEP - 20210512 PL - Egypt TA - Int J Endocrinol JT - International journal of endocrinology JID - 101516376 PMC - PMC8133841 COIS- The authors declare that there are no conflicts of interest regarding this paper. EDAT- 2021/06/01 06:00 MHDA- 2021/06/01 06:01 PMCR- 2021/05/12 CRDT- 2021/05/31 06:09 PHST- 2021/01/18 00:00 [received] PHST- 2021/04/29 00:00 [accepted] PHST- 2021/05/31 06:09 [entrez] PHST- 2021/06/01 06:00 [pubmed] PHST- 2021/06/01 06:01 [medline] PHST- 2021/05/12 00:00 [pmc-release] AID - 10.1155/2021/5525112 [doi] PST - epublish SO - Int J Endocrinol. 2021 May 12;2021:5525112. doi: 10.1155/2021/5525112. eCollection 2021.